treatment

Managing PNH Complications from the Chapel Hill Patient and Family Conference

Topic(s)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Presenter(s)

Srinivasa Reddy Sanikommu, MD

In this recording, Dr. Srinivasa Sanikommu discusses complications that can occur during a PNH patient's lifetime and the treatment options available to patients.

Transplant and GVHD from the 2025 Chapel Hill Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

Bone Marrow Transplant

Presenter(s)

Jeremy A. Meier, MD, PhD

In this recording, Dr. Jeremy Meier discusses the journey of a transplant (before, during and after) and potential management of GVHD.

Aplastic Anemia from the 2025 Chapel Hill Patient and Family Conference

Thumbnail for video Watch Now

Topic(s)

COVID-19

Presenter(s)

Brandi Reeves, MD

In this recording, Dr. Brandi Reeves discusses the diagnosis of aplastic anemia and the treatment options available to patients.

Cyclophosphamide and Cyclosporin for GVHD Prevention

Original Publication Date

October 1, 2025

Article Source

External Web Content

Curtis et al. (July 17 issue)1 report evidence of longer graft-versus-host disease (GVHD)–free, relapse-free survival with post-transplantation cyclophosphamide–based prophylaxis than with cyclosporin–methotrexate among patients receiving a stem-cell transplant from a matched…

Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes/Neoplasms: A Systematic Review and Meta-Analysis

Original Publication Date

September 18, 2025

Article Source

External Web Content

Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). This systematic review and meta-analysis aims to evaluate the efficacy and safety of luspatercept in LR-MDS. We conducted a systematic review and…

Azacitidine as therapy for VEXAS syndrome

Original Publication Date

September 18, 2025

Article Source

External Web Content

How should patients with VEXAS (an acronym for vacuoles [in myeloid and erythroid precursors], E1 enzyme, X-linked, autoinflammatory, somatic) syndrome be treated? Until now, we have only had case reports and small series to guide us. In this issue of Blood, Jachiet and…

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

Original Publication Date

August 13, 2025

Article Source

External Web Content

Abstract Higher-risk myelodysplastic syndrome (HR-MDS) with RARA gene overexpression is a subset of patients (pts) with an actionable target for tamibarotene, an oral and a selective retinoic acid receptor-α (RAR-α) agonist. Tamibarotene with azacitidine (AZA) showed complete…